HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

The response rate to EGFR tyrosine kinase inhibitors (TKIs) may be poor and unpredictable in cancer patients with EGFR expression itself being an inadequate response indicator. There is limited understanding of the mechanisms underlying this resistance. Furthermore, although TKIs suppress the growth...

Full description

Bibliographic Details
Main Authors: Anthony Kong, Véronique Calleja, Pierre Leboucher, Adrian Harris, Peter J Parker, Banafshé Larijani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-08-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2483931?pdf=render

Internet

http://europepmc.org/articles/PMC2483931?pdf=render

Similar Items